e-ISSN 2329-0072

Logo

Medical
MSM  BR

AmJCaseRep

Diagnostic Value of the Tumor Marker Tumor M2-PK in Lung Cancer

Gerhard M Oremek, Dominika Berent, Maciej Wojdyn, Krzysztof Kaczmarek, Paweł Ptaszyński

Med Sci Tech 2006; 47(1): RA35-38

ID: 881490

Available online:

Published: 1999-11-30


Background: We investigated the usefulness of Tumor M2-PK, an isoform of the glycolytic enzyme pyruvate kinase, for diagnosis, treatment and monitoring of patients with lung cancer. This is of ormexistsinan active tetrameric and less active dimeric form. The less active for misexpressed by various tumor cell sand can be measured in blood. Objectives: The aim of this study was to evaluate the individual diagnostic relevance of Tumor M2PK in patients with lungcancer. Material and Methods: Our study comprised 140 patients with lung carcinoma of differenthistologicalcelltypes.Serawere collected and tumour markers as Cyfra 21-1, NSE, SCC and Tumor M2-PK were determined. Tumor M2-PK was measured by an ELISA test of ScheBoTech. The test is a two step sandwich immuno as say using one monoclonalanti body. Moreover serum marker levels were analyzed in 195 healthy volunteers serving as control group. Results: At a specifityof95% the cut-off value was found to beat 12.9kU/l.In patients with squamous cell carcinoma Tumor M2-PK was elevated in 78%, in patients with adenocarcinoma in 73% and in patients with non-small-cell-lung-carcinoma in 81% of the cases. In patients with benign lung diseases such as bronchitis or tuberculosis we have not seen a significant elevation of Tumor M2-PK as the serum concentrations were within the normal range. Conclusion: In conclusion Tumor M2-PK levels are abnormally elevated in patients with lung cancer. Tumor M2-PK might be helpful in the diagnostic procedure in patients supposed to suffer from alungcarcinoma. More over Tumor M2-PK seems to exceed the diagnostic relevance of SCC and NSE in patients with lung carcinoma. (Clin. Exp. Med. Lett. 2006; 47(1):35-38)

Keywords: Tumour-Markers, Pyruvate Kinase, Tumor M2-PK, small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC), Smoker, non-smoker



Back